CITCO Directly Binds to and Activates Human Pregnane X Receptor

Wenwei Lin¹, Monicah Bwayi¹, Jing Wu¹, Yongtao Li, Sergio C. Chai, Andrew D. Huber and Taosheng Chen*

From the Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital,

Memphis, Tennessee 38105

¹These authors contributed equally to this article

118513

Running title: CITCO Is an Agonist of hPXR

*To whom correspondence should be addressed: Taosheng Chen, Department of Chemical Biology & Therapeutics, MS 1000, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA, Tel: (901) 595-5937; Fax: (901) 595-5715; E-mail: <u>taosheng.chen@stjude.org</u>

Number of Text Pages: 34 Number of Tables: 0 Number of Figures: 7 Number of References: 38 Number of words in Abstract: 243 Number of words in Introduction: 695 Number of words in Discussion: 972 Supporting Information: 1 figure (Supplemental Figure 1)

ABBREVIATIONS:

CAR, constitutive androstane receptor; CITCO, 6-(4-chlorophenyl)imidazo [2,1-b][1,3]thiazole-5carbaldehyde-O-(3,4-dichlorobenzyl)oxime; CYP, cytochrome P450; DMSO, dimethylsulfoxide; hCAR, human CAR; hCAR-KO, hCAR knockout; hPXR, human PXR; hPXR-KO, hPXR knockout; LBD, ligand-binding domain; mPXR, mouse PXR; PHH, primary human hepatocyte; PXR, pregnane X receptor; RIF, rifampicin; RXR, retinoid X receptor; SRC-1, steroid receptor coactivator 1; TR-FRET, time-resolved fluorescence resonance energy transfer; WT, wild type.

118513

ABSTRACT

The xenobiotic receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are activated by structurally diverse chemicals to regulate the expression of target genes, and they have overlapping regulation in terms of ligands and target genes. Receptor-selective agonists are, therefore, critical for studying the overlapping function of PXR and CAR. An early effort identified 6-(4chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime (CITCO) as a selective human CAR (hCAR) agonist, and this has since been widely used to distinguish the function of hCAR from that of human PXR (hPXR). The selectivity was demonstrated in a green monkey kidney cell line, CV-1, in which CITCO displayed >100-fold selectivity for hCAR over hPXR. However, whether the selectivity observed in CV-1 cells also represented CITCO activity in liver cell models was not hitherto investigated. In this study, we showed that CITCO (1) binds directly to hPXR; (2) activates hPXR in HepG2 cells, with activation being blocked by an hPXR-specific antagonist, SPA70; (3) does not activate mouse PXR (mPXR); (4) depends on tryptophan-299 to activate hPXR; (5) recruits SRC-1 to hPXR; (6) activates hPXR in HepaRG cell lines even when hCAR is knocked out: and (7) activates hPXR in primary human hepatocytes. Together, these data indicate that CITCO binds directly to the hPXR ligand-binding domain to activate hPXR. As CITCO has been widely used, its confirmation as a dual agonist for hCAR and hPXR is important for appropriately interpreting existing data and designing future experiments to understand the regulation of hPXR and hCAR.

SIGNIFICANCE STATEMENT: The results of this study demonstrate that CITCO is a dual agonist for hCAR and hPXR. As CITCO has been widely used to activate hCAR, and hPXR and hCAR have distinct and overlapping biological functions, these results highlight the value of receptor-selective agonists, and the importance to appropriately interpret data in the context of receptor selectivity of such agonists.

118513

INTRODUCTION

Xenobiotic receptors pregnane X receptor (PXR) and constitutive and rostane receptor (CAR) transcriptionally regulate the expression of genes encoding drug-metabolizing enzymes (e.g., cytochrome P450 3A4 [CYP3A4] and CYP2B6) and transporters (Bertilsson et al., 1998; Kliewer et al., 1998; Lehmann et al., 1998; Wang et al., 2012). They heterodimerize with retinoid X receptor (RXR) to bind to target gene promoters, and their transcriptional activity is induced by agonists and enhanced by coactivators, such as steroid receptor coactivator 1 (SRC-1) (Oladimeji et al., 2016). Some of the target genes can be upregulated by either receptor. For example, although CYP3A4 and CYP2B6 are the prototypical targets of human PXR (hPXR) and human CAR (hCAR), respectively, both receptors regulate these genes (Faucette et al., 2007; Roth et al., 2008; Xie et al., 2000). hPXR and hCAR induce the expression of target genes by binding to DNA response elements in the proximal promoter and distal enhancer regions of the genes (Faucette et al., 2006; Wang et al., 2012). Some chemicals activate both PXR and CAR, whereas others are specific for one receptor. Potent and selective hPXR agonists such as rifampicin have greatly facilitated the identification of hPXR target genes (Maglich et al., 2002) Similarly, 6-(4-chlorophenyl)imidazo[2,1-*b*][1,3]thiazole-5-carbaldehyde-*O*-(3,4-dichlorobenzyl)oxime (CITCO) was identified (Maglich et al., 2003) and widely used as a selective hCAR activator that preferentially induces CYP2B6 (Auerbach et al., 2005; Faucette et al., 2006; Li et al., 2019). Together with selective hPXR agonists such as rifampicin, CITCO has been used to investigate the distinct and overlapping biological functions of hPXR and hCAR.

In the work that identified CITCO as a selective agonist of hCAR (Maglich et al., 2003), the selectivity for hCAR versus hPXR was evaluated in a green monkey kidney cell line, CV-1, that was transiently transfected with an hCAR- and hPXR-responsive luciferase reporter gene construct (i.e., XREM-CYP3A4-LUC), together with hPXR or hCAR. CITCO displayed >100-fold selectivity for hCAR over hPXR (EC₅₀ values for hCAR and hPXR are 25 nM and ~3 μ M, respectively). Although CITCO is highly selective for hCAR in the CV-1 assay system, it is significant that CITCO weakly activated hPXR,

because CITCO has been widely used as a selective hCAR agonist to distinguish the function of hCAR from that of hPXR. However, how CITCO activates hPXR and whether CITCO activity in CV-1 cells matches that in more physiologically relevant cellular models (e.g., human liver cells) have not been investigated.

hPXR is highly expressed in the human liver to regulate drug metabolism. Physiologically relevant cellular models commonly used to study hPXR function include HepG2 cells (a human hepatocellular carcinoma cell line) and primary human hepatocytes (PHHs). Recently, HepaRG cells, which are terminally differentiated hepatic cells derived from a human hepatic progenitor cell line that retains many characteristics of PHHs, have been used as an alternative to PHHs for studying drug metabolism (Grime et al., 2010; Li et al., 2019), as PHHs are not readily available and often display considerable donor-to-donor variation. In addition, the availability of hCAR-KO and hPXR-KO HepaRG cell lines enables investigations of hPXR- and hCAR-dependent and -independent regulation at the genetic level (Li et al., 2019). Recently, a potent and selective hPXR antagonist, SPA70 (Chai et al., 2019; Lin et al., 2017a; Lin et al., 2017b) has been used to investigate hPXR-dependent biological effects *in vitro* and *in vivo* (Li et al., 2019; Xie et al., 2019). Thus, SPA70 is a valuable pharmacologic tool for investigating the specific activation of hPXR.

In this study, we first showed that CITCO binds directly to the hPXR ligand-binding domain (LBD). As the role of CITCO in inducing CYP2B6 through hCAR has been extensively studied, we focused on the regulation of CYP3A4 by CITCO through hPXR in our cell-based assays, using HepG2, HEK293, HepaRG, and PHH cells. We showed that CITCO activates wild-type hPXR, but not hPXR-W299A or mPXR. The effect of CITCO was inhibited by SPA70, but not by hCAR knockout. Together, our data clearly indicate that CITCO binds to and activates hPXR. Our demonstration that CITCO is a dual agonist of hCAR and hPXR provides important information for interpreting previously reported data, as well as for designing future experiments to investigate the overlapping function of hCAR and hPXR.

118513

MATERIALS AND METHODS

Materials. HepG2 (ATCC CRL-10741) human hepatocellular carcinoma and HEK293 (ATCC CRL-1573) cell lines, Eagle's Minimum Essential Medium (EMEM), and Dulbecco's Modified Eagle's Medium (DMEM) were purchased from the American Type Culture Collection (ATCC, Manassas, VA). Cell lines were authenticated by short tandem repeat DNA profiling. Penicillin-streptomycin and puromycin stock solutions, Opti-MEM Reduced Serum Medium, phenol red-free Dulbecco's Modified Eagle Medium, Lipofectamine 3000 Reagent, dimethylsulfoxide (DMSO), Tb-anti-GST, GST-hPXR-LBD, Tris (pH 7.5, 1 M), and DTT (1 M) were purchased from Thermo Fisher Scientific (Atlanta, GA). MgCl₂ (1 M) was purchased from Boston BioProducts (Ashland, MA). Rifampicin, pregnenolone-16acarbonitrile (PCN) and bovine serum albumin (BSA) were purchased from Sigma (St. Louis, MO). CITCO was purchased from Tocris Bioscience (Minneapolis, MN). T0901317 was purchased from Cayman Chemical (Ann Arbor, MI). SPA70 was synthesized by WuXi App Tec (Wuhan, China). Fetal bovine serum (FBS) and charcoal/dextran-treated FBS were purchased from HyClone (Logan, UT). Dual-Glo luciferase assay reagent was purchased from Promega (Madison, WI). Steadylite HTS reagent and 384-well white tissue culture-treated plates were purchased from PerkinElmer Life and Analytical Sciences (Boston, MA). All other tissue culture consumables (tissue culture flasks, disposable pipettes, and 384-well black low-volume assay plates) were purchased from Corning Incorporated (Tewksbury, MA). FAM-SRC1-B peptide was prepared by the Macromolecular Synthesis Section at St. Jude Children's Research Hospital (Lin and Chen, 2018). BODIPY FL vindoline was synthesized in house as previously reported (Lin et al., 2014). Human hepatoma HepaRG-CAR functional knockout (HepaRG CAR KO) cells (catalog # MTOX1012-1VL), HepaRG 5F parental cells (catalog # MTOX1010-1VL), and William's E medium (catalog # W1878-500ML) were purchased from Sigma-Aldrich (St. Louis, MO). HepaRG Thaw, Plate, & General Purpose Medium Supplement (HPRG770) and serum-free induction medium (HPRG750) were purchased from GIBCO Life Technologies (Frederick, MD). Primary human hepatocytes (PHHs) were obtained through the Liver Tissue Cell Distribution System (PHH-Donor #1 = Case # 19-005; PHH-Donor #2 = Case # 19-007; PHH-Donor #3 = Case # 19-008)

(Pittsburgh, PA). Primary Hepatocyte Maintenance Supplement was purchased from GIBCO (catalog # A15564, lot # 2019822; GIBCO Life Technologies).

Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) PXR Competitive Binding Assay. The TR-FRET PXR competitive binding assay was performed as previously described (Lin et al., 2014) with minor modifications. The PXR TR-FRET assay buffer (50 mM Tris [pH 7.5], 20 mM MgCl2, 0.1 mg/mL BSA, and 0.05 mM DTT) was used for both the TR-FRET PXR coactivator recruitment and TR-FRET PXR binding assays. Briefly, BODIPY FL vindoline (15 µL/well, 133.3 nM) was first dispensed into 384-well low-volume black assay plates. An Echo 555 Acoustic Liquid Handler (Labcyte Inc., San Jose, CA) then dispensed 60 nL/well of the indicated concentrations of tested chemicals, DMSO (as a negative control), or 3.33 mM T0901317 (as a positive control). Finally, 5 µL/well of 20 nM Tb-anti-GST and 20 nM GST-hPXR-LBD was added. The final concentrations for the assay components (in a 20-µL final assay volume per well) were as follows: BODIPY FL vindoline: 100 nM; Tb-anti-GST antibody: 5 nM; GST-hPXR-LBD: 5 nM; DMSO: 0.3%; rifampicin: from 20 µM to 9.8 nM with 1-to-2 dilutions for 12 concentration levels; CITCO: from 20 µM to 9.8 nM with 1-to-2 dilutions for 10 concentration levels; T0901317: from 10 µM to 0.17 nM with 1-to-3 dilutions for 11 concentration levels). In addition, 0.3% DMSO alone and T0901317 (10 µM, with 0.3% DMSO, diluted from 60 nL of 3.33 mM DMSO stock to a 20-µL assay volume) were also included in each plate to serve as negative and positive controls, respectively. With all assay components added, the assay plates were shaken at 900 RPM (80 g) on an IKA MTS 2/4 digital microtiter plate shaker for 1 min then briefly centrifuged at 1,000 rpm (201 g) for 30 s in an Eppendorf 5810 centrifuge equipped with an A-4-62 swing-bucket rotor (Eppendorf AG, Hamburg, Germany). The plates were then protected from light exposure and incubated for 60 min. After incubation, the TR-FRET signal from each well was collected with a PHERAstar FS Microplate Reader (BMG Labtech, Durham, NC). The %Inhibition for each well was calculated using Equation (1),

$$\% Inhibition = 100\% - 100\% \times \frac{(TR - FRET \ Signal_{Chemical} - TR - FRET \ Signal_{Positive})}{(TR - FRET \ Signal_{Negative} - TR - FRET \ Signal_{Positive})}, \tag{1}$$

where *TR-FRET Signal_{Chemical}* is the TR-FRET signal from the respective chemical–treated well, *TR-FRET Signal_{Positive}* is the TR-FRET signal from the positive control well, and *TR-FRET Signal_{Negative}* is the TR-FRET signal from the negative control well as indicated.

Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) PXR Coactivator

Recruitment Assay. The TR-FRET PXR coactivator recruitment assay was performed as previously described (Lin and Chen, 2018) with minor modifications. Briefly, FAM-SRC1-B peptide solution (15 μ L/well, 133.3 nM) was first dispensed in 384-well black low-volume assay plates. Various concentrations of tested chemicals (as stock solutions in DMSO), T0901317 (3.33 mM), or DMSO were then dispensed at 60 nL/well with the Echo 555 Acoustic Liquid Handler. Finally, 5 µL/well of 20 nM Tb-anti-GST antibody and 20 nM GST-hPXR-LBD protein were added. The final assay volume per well was 20 µL, and the final concentrations for the assay components were as follows: FAM-SRC1-B peptide: 100 nM; Tb-anti-GST antibody: 5 nM; GST-hPXR-LBD protein: 5 nM; DMSO: 0.3% in all assay wells; rifampicin and CITCO: from 20 µM to 9.8 nM with 1-to-2 dilutions for 12 concentration levels; and T0901317: 10 µM to 0.17 nM with 1-to-3 dilutions for 11 concentration levels. In addition, 0.3% DMSO alone and 10 µM T0901317 with 0.3% DMSO (diluted from 60 nL of 3.33 mM DMSO stock to 20 μ L assay volume) were also included in each plate to serve as the vehicle background and reference controls, respectively. The assay plates with all assay components added were shaken at 900 RPM (80 g) for 1 min with an IKA MTS 2/4 digital microtiter plate shaker (IKA Works, Wilmington, NC) then briefly centrifuged at 1,000 rpm (201 g) for 30 s in an Eppendorf 5810 centrifuge equipped with an A-4-62 swing-bucket rotor (Eppendorf AG, Hamburg, Germany). The plates were then incubated for 60 min, while protected from light exposure, and the TR-FRET signals from individual wells were collected with a PHERAstar FS Microplate Reader (BMG Labtech, Durham, NC) after incubation. The fold-to-DMSO TR-FRET signals of each chemical at its respective concentrations then were calculated.

118513

Cell Culture, Plasmids, and Transfection. All cells were maintained at 37°C in a humidified atmosphere containing 5% CO₂. HEK293 cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% FBS, 100 units/mL penicillin, and 100 µg/mL streptomycin. HepG2 cells were maintained in Eagle's Minimum Essential Medium (EMEM) supplemented with 10% FBS, 100 units/mL penicillin, and 100 µg/mL streptomycin. Cells were routinely verified to be mycoplasma free by using a MycoProbe Mycoplasma Detection Kit (R&D Systems, Minneapolis, MN). FLAG-hPXR and CYP3A4-luciferase in pGL3 vector have been previously described (Lin et al., 2008). The CYP3A4 promoter in pGL3-CYP3A4-luciferase (Lin et al., 2008) was subcloned into pGL4.20 (Promega) to generate the pGL4.20-CYP3A4-luciferase, which was co-transfected with FLAG-hPXR into HepG2 cells. Stable cells were selected in medium containing 1 mg/mL G418 and 5 µg/mL Puromycin for 4 weeks. The HepG2 cells stably expressing FLAG-hPXR and CYP3A4-luciferase were maintained in EMEM supplemented with 10% FBS, 2 µg/mL Puromycin, and 400 µg/mL G418. Cells were grown to 70%–80% confluence before being harvested for subcultures, transfections, or assays. Human hepatoma HepaRG-CAR functional knockout (HepaRG CAR KO) cells (catalog # MTOX1012-1VL) and HepaRG 5F cells (HepaRG parental cells) (catalog # MTOX1010-1VL) were grown in culture in Williams' Medium E supplemented with HepaRG Thaw, Plate, & General Purpose Medium Supplement, 100 U/mL penicillin, and 100 µg/mL streptomycin for 14 days, then maintained for a further 14 days in medium containing 1.5% DMSO to differentiate the cells. Primary human hepatocytes were obtained through the Liver Tissue Cell Distribution System and were maintained in Williams' Medium E supplemented with Primary Hepatocyte Maintenance Supplement.

Transient transfections of HEK293 cells were performed using Lipofectamine 3000 Reagent. Briefly, transfection mixture containing 625 μ L of Opti-MEM Reduced Serum Medium with 5.0 μ g of *CYP3A4*-luciferase plasmid DNA (Lin et al., 2008; Wang et al., 2013) and 0.25 μ g of pRL-TK plasmid DNA (encoding *Renilla* luciferase as a control reporter) (Promega), with or without 0.25 μ g of FLAG-hPXR-W299A (Banerjee et al., 2016), or 0.25 μ g of CMV6-mPXR Kana-R

(OriGene Technologies, Rockville, MD), along with 12.5 μ L of P3000 reagent and 12.5 μ L of Lipofectamine 3000 reagent, was mixed with 4 million HEK293 cells in 5 mL of Opti-MEM Reduced Serum Medium supplemented with 10% FBS. The transfection mixture was prepared in accordance with the manufacturer's instructions. The HEK293 cell solutions mixed with the individual transfection mixtures were then transferred to T25 tissue culture flasks, and the HEK293 cells were transfected overnight before being harvested for compound treatments.

Luciferase Reporter Assays. For the luciferase assays using transfected HEK293 cells, the transfected cells were harvested and resuspended in phenol red-free DMEM supplemented with 5% charcoal/dextran-treated FBS at 0.2 million cells/mL. The resuspended transfected HEK293 cells (25 μ L/well, corresponding to 5,000 cells) were dispensed into 384-well white tissue culture–treated plates. For single compound treatment, the Echo 555 Acoustic Liquid Handler was used to dispense 75 nL/well of stock dilutions of chemicals in DMSO or DMSO only (as a negative control) into the corresponding wells. The final concentrations of rifampicin, CITCO, and PCN ranged from 10 µM to 0.5 nM, with 1-to-3 dilutions for 10 concentration levels. The final DMSO concentration was 0.3% in all HEK293-based assays with single compound treatment. In co-treatments with dilutions of rifampicin and fixed concentration of CITCO, the Echo 555 Acoustic Liquid Handler dispensed 25 nL/well of stock dilutions of rifampicin in DMSO, in addition to 25 nL/well of DMSO, 1 mM CITCO, 2.5 mM CITCO, 5 mM CITCO or 10 mM CITCO. The final concentrations of rifampicin ranged from 4.88 nM to 10 µM in a 1to-2 dilution pattern combined with 0, 1, 2.5, 5 or 10 μ M of CITCO. In co-treatments with dilutions of CITCO and fixed concentration of rifampicin, the Echo 555 Acoustic Liquid Handler dispensed 25 nL/well of stock dilutions of CITCO in DMSO, in addition to 25 nL/well of DMSO, 0.1 mM rifampicin, 0.25 mM rifampicin, 0.5 mM rifampicin, 1 mM rifampicin or 5 mM rifampicin. The final concentrations of CITCO ranged from 4.88 nM to 10 µM in a 1-to-2 dilution pattern combined with 0, 0.1, 0.25, 0.5, 1 or 5 µM of rifampicin. The final DMSO concentration was 0.2% in the rifampicin and CITCO combination study. The chemical-treated cell plates were then incubated overnight at 37°C in a humidified atmosphere

containing 5% CO₂, after which a Dual-Glo luciferase assay (Promega) was performed. The luminescence signals from each plate were collected with an Envision HTS Multilabel Plate Reader (Model 2102; PerkinElmer Life and Analytical Sciences, Boston, MA). The firefly luciferase signals were normalized to the respective *Renilla* luciferase signals to derive normalized luciferase signals. The relative luciferase signals for each chemical at its respective concentrations were calculated by dividing the normalized luciferase signals for the chemical by the normalized luciferase signals for the DMSO (the negative control).

For the luciferase assays with the HepG2 hPXR-CYP3A4-luciferase stable cells, a protocol was adopted that was similar to that for the HEK293 cells, except that a slightly different drug-treatment regimen was used. In the single-compound dose-response test, the Echo 555 Acoustic Liquid Handler dispensed 75 nL/well of stock dilutions of chemicals in DMSO or DMSO only into 384-well white tissue culture-treated plates, along with an additional 25 nL/well DMSO (to serve as a vehicle control when compared to treatments with two compounds). The final concentrations of rifampicin, CITCO, and SPA70 ranged from $20 \,\mu\text{M}$ to 0.61 nM with 1-to-2 dilutions for 16 concentration levels. In the two-compound combination test (using dilutions of rifampicin or CITCO, along with various fixed concentrations of SPA70), the Echo 555 Acoustic Liquid Handler dispensed 75 nL/well of stock dilutions of rifampicin or CITCO in DMSO or DMSO only into 384-well white tissue culture-treated plates, along with an additional 25 nL/well of SPA70 DMSO stock (10 mM, 2 mM, 1 mM, 500 µM, or 100 µM) or DMSO alone. The final rifampicin and CITCO concentrations ranged from 20 µM to 9.8 nM with 1-to-2 dilutions for 12 concentration levels (in the presence of 10 µM, 2 µM, 1 µM, 500 nM, 100 nM, or 0 nM SPA70 as indicated). The final DMSO concentration was 0.4% (negative control) in all HepG2 hPXR-CYP3A4-luciferase stable cell-based assays. The chemical-treated cell plates were then incubated overnight at 37°C in a humidified atmosphere containing 5% CO₂, after which the luciferase was assayed using the Steadylite HTS reagent. The luminescence signals for each plate were collected using the Envision HTS Multilabel Plate Reader. The relative luciferase signals for each chemical at its respective concentrations were calculated by dividing the

firefly luciferase signals from the compound by that from the DMSO control and expressed as relative luciferase unit (RLU).

Cytotoxicity Assays. In the HEK293 and HepG2 hPXR-CYP3A4-luciferase stable cell-based cytotoxicity assays, assay plates were prepared identically to those for the luciferase reporter assays. In addition, designated wells without cells but with other assay components present were included in each assay plate. After an overnight incubation, the chemical-treated plates were subjected to cytotoxicity assays using the CellTiter-Glo Luminescent Cell Viability Assay reagent (Promega). The luminescence signals for each plate were collected using the Envision HTS Multilabel Plate Reader. The DMSO wells with cells served as negative controls, and the DMSO wells without cells served as positive controls. The %relative cytotoxicity for each well was calculated using Equation (2),

$$\% Relative Cytotoxicity = 100\% \times \frac{(Lumi_{Negative} - Lumi_{Chemical})}{(Lumi_{Negative} - Lumi_{Positive})},$$
(2)

where *Lumi_{Negative}* is the luminescence signal from the negative control group, *Lumi_{Chemical}* is the luminescence signal from the respective chemical-treated well, and *Lumi_{Positive}* is the luminescence signal from the positive control group.

Dose-Response Data Analysis. In the luciferase reporter, cytotoxicity, TR-FRET PXR competitive binding, and TR-FRET PXR coactivator recruitment assays, chemicals were tested in quadruplicate at least three times. For the dose-response data analysis, the relative luciferase signals in the luciferase assays, the relative cytotoxicity in the cytotoxic assays, the %inhibition in the PXR TR-FRET competitive binding assays, and the fold-to-DMSO TR-FRET signal in the PXR TR-FRET coactivator recruitment assays of each chemical at the corresponding concentrations were plotted using GraphPad PRISM software (version 8.1.1, GraphPad Software, San Diego, CA) to derive the dose-response curve and corresponding IC₅₀ or EC₅₀ values, if applicable, via the built-in sigmoidal dose-response fitting equation.

118513

Computational Docking Studies. In silico docking of CITCO to hPXR was performed using the GLIDE module (Halgren et al., 2004) from Schrodinger v11.6. The structure of CITCO was prepared using the Ligprep module, where the structure was converted from 2D to 3D format, hydrogen atoms were added and possible ionization states at pH 7 were generated (Sastry et al., 2013). The crystal structure of hPXR LBD (Lin et al., 2017b) was obtained from the RCSB Protein Data Bank (PDB code: 5X0R). Chain B was processed using the Protein Preparation Wizard in the Maestro suite from Schrodinger to remove water molecules, and include correct hetero atom bond order and protonation state (Kumar et al., 2018). Molecular docking experiments were executed using the Ligand Docking protocol (SP-mode) in the Maestro suit from Schrodinger with the grid set to encompass the ligand binding site of hPXR LBD, and the poses were ranked based on scores provided by GLIDE (Tahlan et al., 2019).

RNA Isolation and Quantitative Real-Time Polymerase Chain Reaction Analysis (qRT-PCR).

Primary human hepatocytes were seeded in collagen I–coated 6-well plates. Upon receipt from provider, Williams' Medium E supplemented with Primary Hepatocyte Maintenance Supplement was used to replace the shipping medium, and the PHHs were grown for 24 h, after which they were induced with the respective compounds dissolved in DMSO for an additional 72 h in fresh Williams' Medium E supplemented with Primary Hepatocyte Maintenance Supplement. Differentiated HepaRG cells were seeded in 24-well plates at 0.4 × 10⁶ cells/well and maintained in Williams' Medium E supplemented with HepaRG Thaw, Plate, & General Purpose Medium Supplement (HPRG770, Invitrogen) for 3 days. The cells were then treated with the respective chemicals for 24 h in Williams' Medium E supplemented with serum-free induction medium (HPRG750, Invitrogen). Final DMSO concentration was 0.1% (for both PHHs and HepaRG cells). Total RNA was isolated from the cells by using Maxwell 16 LEV SimplyRNA Tissue Kits (Promega). In each case, cDNA was generated from 2 µg of RNA by using a SuperScriptTM VILOTM cDNA Synthesis Kit (Invitrogen). Five microliters of diluted cDNA (1:10) was used to perform quantitative RT-PCR in an ABI 7900HT system (Applied Biosystems), using TaqMan gene expression assays specific for *CYP3A4* (Hs00604506 m1), with *RNA18S* (Hs03928990 g1) being used as reference genes (Applied Biosystems).

Thermo Fisher Scientific, Waltham, MA). Fold induction values were calculated according to the following equation: fold change = $2^{-\Delta\Delta Ct}$, where ΔCt represents the differences in cycle threshold numbers between the target gene and reference gene and $\Delta\Delta Ct$ represents the relative change in these differences between the control and treatment groups.

Mammalian Two-Hybrid Assay. For these assays, the CheckMate Mammalian Two-Hybrid System (Promega) was used. The pG5-luc, pACT-hPXR, and pBIND-SRC-1 plasmids have been described previously (Wang et al., 2013). For this study, pACT-hPXR LBD containing residues 139-434 of hPXR LBD was generated with the Q5 Site-Directed Mutagenesis Kit (New England Biolabs) using primers 5'-GGAGTGCAGGGGCTGACAGAGGAGCAGCGGATGATGATC-3' and 5'-

GTGTCGACGGATCCCTGGCGATCC-3' and the previously described pACT-hPXR as template. For each assay, 1 μ g of the pG5-luc, and 0.5 μ g each of the pACT-hPXR LBD, and pBIND-SRC-1 vector constructs (a 2:1:1 ratio) was transfected into HepG2 cells in 6-well plates. The respective empty vector constructs were used as controls. The pG5-luc construct contains five Gal4 binding motifs and expresses firefly luciferase, whereas the pBIND–SRC-1 vector expresses *Renilla* luciferase as an internal transfection control. Twenty-four hours after transfection, the cells were transferred into 96-well plates and treated with 0.1% DMSO, 5 μ M rifampicin, or CITCO (1 or 10 μ M) for an additional 24 h. A Dual-Glo Luciferase Assay Kit (Promega) was used to measure both the firefly luciferase activity and the *Renilla* luciferase activity. The relative luciferase activity was obtained by normalizing the firefly luciferase activity to the *Renilla* luciferase activity.

Western Blot Analysis. HepaRG cells and PHHs were treated with the respective chemical compounds for 72 h in 6-well plates, with the compound/medium being replaced each day. Cells were rinsed with cold phosphate-buffered saline (PBS) and harvested using a cell scraper in RIPA lysis buffer (25 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1% Nonidet P-40, 1% sodium deoxycholate, and 0.1% SDS) with 1× protease inhibitors. Then, for each sample, 40 µg of protein (lysate) was loaded onto NuPAGE 4– 12% Bis-Tris Protein Gels (Invitrogen) and electrophoretically separated using 1× NuPAGE MES

118513

running buffer. The proteins were then transferred to a nitrocellulose membrane by using an iBlot Gel Transfer Device (Invitrogen). The membranes were blocked with 5% skim milk for 1 h then probed with mouse monoclonal antibodies against CYP3A4 (K03) (Schuetz et al., 1996) or β-actin (A5441; Sigma). This step was followed by incubation with a secondary goat anti-mouse antibody (IR-dye 800CW; LI-COR Biosciences), and protein bands were visualized with an Odyssey infrared imager (LI-COR Biosciences).

Statistical Analysis. Results are expressed as the mean \pm SD of at least three independent experiments. Significance was established when P < 0.05. Student's *t*-test was used for comparisons of the means of two groups as specified. All qRT-PCR graphs were generated using Graphpad PRISM 8. For qRT-PCR, analysis and experimental significance was established using One-way ANOVA followed by Dunnett's multiple comparison test for all samples compared to the DMSO control. For the mammalian two-hybrid assay, samples were analyzed using 2-way ANOVA followed by Sidak's multiple comparisons test.

118513

RESULTS

CITCO Binds Directly to hPXR. To determine whether CITCO bound directly to the hPXR LBD, we used an *in vitro* TR-FRET competition ligand-binding assay that employed an hPXR-binding probe, BODIPY FL vindoline (Lin et al., 2014). T0901317, a potent hPXR agonist, was used as a positive control. T0901317 inhibited the binding of BODIPY FL vindoline to hPXR in a dose-responsive manner, with an IC₅₀ value of 36.4 nM (Fig. 1). At a concentration of 10 μ M, T0901317 completely inhibits the binding of BODIPY FL vindoline to hPXR (100% inhibition) (Lin et al., 2014). DMSO was used as a vehicle negative control (0% inhibition). As shown in Fig. 1, CITCO binds to the hPXR LBD and inhibits the binding of BODIPY FL vindoline to hPXR in a dose-dependent manner with an IC₅₀ value of 1.55 μ M. At a concentration of 5 μ M, CITCO displayed a maximal inhibitory activity of 56.2%. The inhibitory activity at the higher concentrations tested (10 and 20 μ M) decreased, possibly due to its poor solubility in the assay system (represented by the dotted line of the CITCO dose response curve in Fig. 1; the inhibitory activities of CITCO at these two high concentrations were not included to derive its IC₅₀ value). The IC₅₀ value for rifampicin is 0.94 μ M. These data indicate that, similar to rifampicin, CITCO binds directly to the hPXR LBD.

CITCO Activates hPXR But Not mPXR. To determine whether CITCO induced hPXR-mediated *CYP3A4* promoter activation, we used HepG2 cells stably expressing FLAG-hPXR and an hPXR-regulated *CYP3A4* promoter luciferase reporter (CYP3A4-luciferase) (Lin et al., 2008; Wang et al., 2013). As shown in Fig. 2A, CITCO activated the *CYP3A4* promoter with an EC₅₀ of 0.82 μ M and the maximal activation represented a 6.94-fold increase over that of the DMSO control at a concentration of 10 μ M. As a reference, rifampicin had an EC₅₀ of 0.81 μ M and the maximal activation represented a 7.04-fold increase over that of the DMSO control (at a concentration of 10 μ M). The activity of CITCO was blocked by a specific hPXR antagonist, SPA70 (Lin et al., 2017b), in a dose-responsive manner (Fig. 2B), indicating that the effect of CITCO on the *CYP3A4* promoter is hPXR dependent. Consistent with a previous report (Lin et al., 2017b), SPA70 also inhibited rifampicin in a dose-responsive manner (Fig. 2C). At a concentration of 10 μ M,

SPA70 completely inhibited all concentrations of both rifampicin and CITCO. These three compounds exhibited very low toxicity in corresponding cytotoxicity assays (Fig. 2 D–F), confirming that the antagonistic effect of SPA70 on rifampicin and CITCO is not due to its cytotoxicity.

HepG2 cells have low levels of endogenous hPXR and hCAR (Yokobori et al, 2019), and both hPXR and hCAR regulate CYP3A4 promoter activity. To further confirm the hPXR-activating effect of CITCO, we used the human embryonic kidney cell line HEK293, which does not express endogenous hPXR or hCAR. In HEK293 cells transiently transfected with CYP3A4-luciferase and pRL-TK (encoding Renilla luciferase as a transfection control), with ectopic expression of hPXR-WT (Fig. 3A), but not of a vector control (Fig. 3B), CITCO induced hPXR-mediated CYP3A4 promoter activation, further confirming the agonistic effect of CITCO on hPXR. As expected, in the hPXR assay, the mouse PXR (mPXR)-specific agonist pregnenolone-16a-carbonitrile (PCN) did not activate hPXR (Fig. 3A) (PCN is, thus, a negative control for hPXR). In HEK293 cells transiently transfected with hPXR, CITCO activated hPXR to a lesser extent when compared to rifampicin (Fig. 3A), which is consistent with the observation noted in the original report that identified CITCO as a selective hCAR agonist that CITCO only weakly activated hPXR when compared to rifampicin in green monkey kidney CV-1 cells. Therefore CITCO is a weaker hPXR agonist than rifampicin in HEK293 cells transiently transfected with hPXR. However, in HepG2 cells stably expressing hPXR, the EC_{50} of CITCO is comparable to that of rifampicin (Fig. 2A). The differential potency of CITCO in HepG2 and HEK293 cells likely reflects the contribution of cellular context to the action of ligands. Using the HEK293 cell model, we also investigated the effect of co-treatment with CITCO and rifampicin on hPXR activation (Supplemental Figure 1). CITCO showed an additive effect with low concentrations of rifampicin, but had no effect on high concentrations of rifampicin. These results are consistent with the observations that while both CITCO and rifampicin are agonists of hPXR, CITCO is weaker than rifampicin in HEK293 cells.

As shown in Fig. 3C, CITCO did not activate mPXR, indicating that the agonistic effect of CITCO is specific for hPXR. As assay controls, hPXR-specific rifampicin (used as a negative control) did not

118513

activate mPXR but PCN (used as a positive control) did so. PCN activates mPXR with an EC₅₀ value of 0.25 μ M, which is consistent with previously reported results (Nallani et al., 2003). As shown in Fig. 3E, the compounds tested have very low cytotoxicity in HEK293 cells. Together, these data indicate that CITCO is an agonist for hPXR but not for mPXR.

The Agonistic Effect of CITCO Depends on Tryptophan-299 of hPXR. Recently, an indirect hCAR activator, phenobarbital, was shown to activate hPXR in a manner that depends on a single aromatic amino acid, tryptophan-299 (Li et al., 2019). Interestingly, mutating tryptophan-299 to alanine (hPXR-W299A) abolished the agonistic effect of CITCO on hPXR (Fig. 3D), indicating that CITCO also depends on tryptophan-299 to activate hPXR. Consistent with previous reports, the W299A mutant also decreased the response to rifampicin (Banerjee et al., 2016; Li et al., 2019).

To understand the structural basis of CITCO-mediated hPXR activation and its dependency on tryptophan-299, we docked the structure of CITCO to the ligand binding pocket of hPXR LBD (Fig. 4). The preferred computational docking pose suggests that CITCO interacts with multiple residues of hPXR with mostly hydrophobic character. Notably, the 3,4-dichlorobenzyl ring moiety of CITCO shows a strong π - π interaction with the W299 residue, which could explain the reduction of agonistic activity of hPXR-W299A by CITCO.

CITCO Induces Recruitment of SRC-1 to hPXR. An agonist of hPXR would be expected to bind to hPXR and recruit coactivators such as SRC-1. To investigate whether CITCO exhibited this property, we first employed an *in vitro* hPXR TR-FRET coactivator recruitment assay in which a fluorescently labeled SRC-1 peptide (FAM-SRC1-B) was used as previously reported (Lin and Chen, 2018). As shown in Fig. 5A, CITCO and two known hPXR agonists, T0901317 and rifampicin, recruited SRC-1 peptide to hPXR in a dose-responsive manner. T0901317 is the most potent hPXR agonist and was used as a positive control. Consistent with our previous report (Lin and Chen, 2018), the EC₅₀ value of T0901317 was 110.9 nM, with the maximal TR-FRET signal (shown as the fold increase over that of the

DMSO vehicle control) being 4.43-fold at 3.33 μ M and 4.18-fold at 10 μ M. The maximal TR-FRET signals for CITCO and rifampicin were 2.20-fold at 20 μ M and 1.35-fold at 20 μ M, respectively (Fig. 5A).

We further examined the CITCO-induced hPXR recruitment of SRC-1 in cells by using the mammalian two-hybrid assay, using rifampicin as a positive control. As shown in Fig. 5B, in the absence of hPXR (Gal4-SRC-1 and VP16-AD vector control), neither rifampicin nor CITCO enhanced the basal (DMSO) luciferase reporter signal. In the presence of hPXR LBD (Gal4-SRC-1 and VP16-hPXR), the basal luciferase reporter signal (DMSO) increased, reflecting the basal interaction level between hPXR and SRC-1. As expected, the interaction was increased by rifampicin (5 μ M). CITCO also enhanced the hPXR/SRC-1 interaction in a dose-responsive manner (at 1 and 10 μ M). Together with data shown in Figs. 1–4, these data indicate that CITCO binds to the hPXR LBD to activate hPXR by recruiting the coactivator SRC-1.

CITCO Induces *CYP3A4* Expression in HepaRG Cell Models Independent of hCAR. To confirm our observations made in HepG2 and HEK293 cells that CITCO activates hPXR, we took advantage of HepaRG cell models (using parental and hCAR knockout cells). HepaRG cells are hepatic cells derived from a human hepatic progenitor cell line, and they retain many features of PHHs, including the endogenous expression of hPXR and hCAR as well as CYPs (e.g., CYP3A4 and CYP2B6). As expected, 5 μ M rifampicin robustly induced the expression of CYP3A4 at both the mRNA and protein levels (Figs. 6A and 6B). CITCO at all concentration tested (0.2, 1, and 10 μ M) also increased both the mRNA and protein levels of CYP3A4 (Figs. 6A and 6B). SPA70 is an hPXR-specific antagonist that does not inhibit hCAR (Lin et al., 2017b). The inducing effect of both rifampicin is an hPXR-specific agonist and SPA70 an hPXR-specific antagonist and indicates that, like rifampicin, CITCO depends on hPXR to induce CYP3A4.

To further confirm that CITCO induces CYP3A4 primarily through hPXR and not through hCAR, we used differentiated HepaRG cells in which hCAR had been knocked out (HepaRG CAR KO cells). In

118513

the absence of hCAR, CITCO, as well as rifampicin, could still enhance CYP3A4 mRNA and protein levels (Figs. 6C and 6D). Furthermore, both rifampicin- and CITCO-induced CYP3A4 expression were abolished by SPA70 (Figs. 6D and 6E). The observations that SPA70, but not knockout of hCAR in HepaRG cells, abolished the inducing effect of CITCO on CYP3A4 induction clearly indicate that CITCO is an agonist of hPXR and that it induces the expression of CYP3A4 primarily through hPXR.

CITCO Induces CYP3A4 Expression in Primary Human Hepatocytes in an hPXR-Dependent

Manner. We further evaluated the agonistic effect of CITCO on hPXR by using PHHs (from three different donors). PHH is the gold-standard model for evaluating xenobiotics and xenobiotic receptor-mediated expression of drug-metabolizing enzymes. Consistent with our observations in HepG2 and HepaRG cells, CITCO induced CYP3A4 mRNA and protein levels to varying extents that reflected the expected donor-to-donor variation (Fig. 7); however, the inductive effect of CITCO on CYP3A4 was consistently inhibited by SPA70. Rifampicin was used as a control; it induced *CYP3A4* mRNA robustly, but its inducing effect was attenuated by SPA70. Taken together, these data suggest that CITCO induces CYP3A4 by activating hPXR.

118513

DISCUSSION

PXR and CAR are the master xenobiotic receptors with overlapping regulation in terms of the ligands that activate them (such as rifampicin and CITCO) and the target genes (such as CYP2B6 and CYP3A4) they regulate (Chai et al., 2016; Chai et al., 2019). Some chemicals activate both PXR and CAR, whereas others are specific for one receptor. For example, the antimalarial artemisinin and the antipsychotic chlorpromazine activate both hPXR and hCAR (Burk et al., 2005; Faucette et al., 2007), whereas the antibiotic rifampicin and the synthetic small molecule SR12813 selectively activate hPXR (Bertilsson et al., 1998; Blumberg et al., 1998; Jones et al., 2000; Lehmann et al., 1998). Our understanding of the specific regulation of PXR and CAR in cell models in which both PXR and CAR are endogenously expressed has been facilitated by experimental genetic downregulation (as in knockdown or knockout studies) (Cheng et al., 2011) and by the development of small modulators that specifically regulate each receptor (Chai et al., 2016). Alternatively, non-physiologically relevant cell models lacking endogenous expression of PXR or CAR (such as HEK293 and CV-1 cells) have been used to study each receptor individually by expressing it ectopically (Maglich et al., 2003). When using small molecule modulators to study receptor-specific regulation in cell models endogenously expressing both PXR and CAR, the selectivity of the small molecule modulators is crucial for the study outcomes to be meaningful.

Since CITCO was identified as a selective hCAR agonist (Maglich et al., 2003), it has been widely used to investigate the selective regulation of hPXR and hCAR (Li et al., 2019), although it was known that CITCO activates hPXR in CV-1 cells with an EC_{50} of ~3 μ M. However, whether and how CITCO activates hPXR in more physiologically relevant models, such as liver cell models, has hitherto been unknown. In our study, we have provided the first evidence to show that CITCO directly binds to hPXR. Enabled by the recent development of the specific hPXR antagonist SPA70, we showed that in three liver cell models (HepG2, HepaRG, and PHH cells), CITCO induces CYP3A4 expression in an hPXR-dependent manner. By using HepaRG cells with CAR KO, we

clearly showed that CITCO induces CYP3A4 independently of hCAR. hPXR and mPXR have very different ligand profiles, and as expected, CITCO does not activate mPXR. Recently, W299 of hPXR has been shown to control the agonistic efficacy of many hPXR ligands (Banerjee et al., 2016; Li et al., 2019). Consistent with the important role of W299 in regulating ligand efficacy, we showed that the agonistic effect of CITCO also requires W299. Even though the importance of W299 in PXR's transcriptional activity could be correlated to its significant intermolecular interactions with the aromatic group of CITCO, more studies are needed to investigate whether the W299A mutation reduces the binding of CITCO to hPXR or decreases activation efficacy (e.g. reducing AF-2 helix stabilization in the agonistic mode). These studies were hampered by the inability to obtain purified hPXR-LBD-W299A due to protein instability. We also showed that CITCO recruits the co-activator SRC-1 to hPXR in both *in vitro* and mammalian two-hybrid assays. Thus, our study comprehensively establishes CITCO as an agonist of hPXR that interacts directly with the hPXR LBD, involves W299, and recruits SRC-1 to carry out its agonistic function. Therefore, CITCO is a dual agonist of hCAR and hPXR.

There are two commonly used hCAR agonists: CITCO and phenobarbital. CITCO directly binds and activates hCAR, whereas phenobarbital activates hCAR through an indirect signaling mechanism that involves the inhibition of epidermal growth factor receptor signaling (Mutoh et al., 2013). Interestingly, it was recently reported that phenobarbital is also a dual activator of hCAR and hPXR (Li et al., 2019). It is also interesting that most CAR inhibitors (inverse agonists), such as PK11195, clotrimazole, meclizine, and androstanol, also function as hPXR activators (Cherian et al., 2015). Although we still lack clear structural and mechanistic insights into why and how hPXR binds most, if not all modulators (inhibitors and activators) of CAR and translates the binding of these CAR modulators (regardless whether they activate or inhibit CAR) into cellular activation of hPXR, it appears that hPXR is more promiscuous than CAR in terms of ligand binding, leading to cellular activation of the receptor and the induction of downstream transcriptional targets. Of the two master

xenobiotic receptors, hPXR appears to be a more promiscuous (and, thus, more important) xenobiotic receptor than CAR.

It has also become necessary to carefully re-evaluate the relation between hCAR and hPXR (in terms of both regulation and cellular function). How do they co-regulate target genes? Are they redundant and do they compensate each other? At what levels do they cross-talk (at the ligand binding, target promoter binding, or cofactor-binding levels)? We noticed that in HepaRG CAR knockout cells, the CYP3A4-inducing activity of both rifampicin (most apparently at the mRNA level) and CITCO (at both the mRNA and protein levels) increased when compared to that in parental HepaRG WT cells (Fig. 6). The possibility that these observations indicate a previously unrecognized inhibitory effect of hCAR on hPXR, albeit one that is mechanistically unclear, warrants further investigations into the relation between PXR and CAR. To facilitate such investigations, there is an urgent need to develop hCAR-specific modulators (inhibitors or activators).

In summary, we have clearly shown that CITCO, previously known to be and used as an hCAR-selective agonist, is actually a dual agonist of hPXR and hCAR. As both hPXR and hCAR are now known to play important physiologic and pathologic roles in energy metabolism, inflammation, and cell proliferation, in addition to their roles in drug metabolism (Oladimeji and Chen, 2018), appropriately dissecting the function of hPXR and hCAR with suitable genetic or chemical tools, developed using appropriate cell models, becomes more important for defining the distinct physiologic and pathologic roles of each of these receptors.

118513

ACKNOWLEDGMENTS

We thank the Macromolecular Synthesis Section at St. Jude Children's Research Hospital for preparing the FAM-SRC1-B peptide, other members of the Chen research laboratory for valuable discussions, and Dr. Keith A. Laycock of the St. Jude Department of Scientific Editing for editing the manuscript.

118513

AUTHORSHIP CONTRIBUTIONS

Participated in research design: Lin, Bwayi, Wu, Li, and Chen.

Conducted experiments: Lin, Bwayi, Wu, Li and Huber.

Performed data analysis: Lin, Bwayi, Wu, Li, and Chai.

Wrote or contributed to the writing of the manuscript: Lin, Bwayi, Wu, Li, Chai, Huber and Chen.

REFERENCES

- Auerbach SS, Stoner MA, Su S and Omiecinski CJ (2005) Retinoid X receptor-alpha-dependent transactivation by a naturally occurring structural variant of human constitutive androstane receptor (NR1I3). *Mol Pharmacol* **68**(5): 1239-1253.
- Banerjee M, Chai SC, Wu J, Robbins D and Chen T (2016) Tryptophan 299 is a conserved residue of human pregnane X receptor critical for the functional consequence of ligand binding. *Biochem Pharmacol* 104: 131-138.
- Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, Sydow-Backman M, Ohlsson R, Postlind H, Blomquist P and Berkenstam A (1998) Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. *P Natl Acad Sci USA* 95(21): 12208-12213.
- Blumberg B, Sabbagh W, Jr., Juguilon H, Bolado J, Jr., van Meter CM, Ong ES and Evans RM (1998)SXR, a novel steroid and xenobiotic-sensing nuclear receptor. *Genes Dev* 12(20): 3195-3205.
- Burk O, Arnold KA, Nussler AK, Schaeffeler E, Efimova E, Avery BA, Avery MA, Fromm MF and Eichelbaum M (2005) Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. *Mol Pharmacol* 67(6): 1954-1965.
- Chai SC, Cherian MT, Wang YM and Chen T (2016) Small-molecule modulators of PXR and CAR. *Biochim Biophys Acta* **1859**(9): 1141-1154.
- Chai SC, Lin W, Li Y and Chen T (2019) Drug discovery technologies to identify and characterize modulators of the pregnane X receptor and the constitutive androstane receptor. *Drug Discov Today* **24**(3): 906-915.
- Cheng J, Ma X and Gonzalez FJ (2011) Pregnane X receptor- and CYP3A4-humanized mouse models and their applications. *Br J Pharmacol* **163**(3): 461-468.
- Cherian MT, Lin W, Wu J and Chen T (2015) CINPA1 is an inhibitor of constitutive androstane receptor that does not activate pregnane X receptor. *Mol Pharmacol* **87**(5): 878-889.

- Faucette SR, Sueyoshi T, Smith CM, Negishi M, Lecluyse EL and Wang H (2006) Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor. *J Pharmacol Exp Ther* **317**(3): 1200-1209.
- Faucette SR, Zhang TC, Moore R, Sueyoshi T, Omiecinski CJ, LeCluyse EL, Negishi M and Wang H (2007) Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. *J Pharmacol Exp Ther* **320**(1): 72-80.
- Grime K, Ferguson DD and Riley RJ (2010) The use of HepaRG and human hepatocyte data in predicting CYP induction drug-drug interactions via static equation and dynamic mechanistic modelling approaches. *Curr Drug Metab* 11(10): 870-885.
- Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT and Banks JL (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. *J Med Chem* 47(7): 1750-1759.
- Jones SA, Moore LB, Shenk JL, Wisely GB, Hamilton GA, McKee DD, Tomkinson NC, LeCluyse EL, Lambert MH, Willson TM, Kliewer SA and Moore JT (2000) The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. *Mol Endocrinol* 14(1): 27-39.
- Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA, McKee DD, Oliver BB, Willson TM, Zetterstrom RH, Perlmann T and Lehmann JM (1998) An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. *Cell* 92(1): 73-82.
- Kumar S, Singh J, Narasimhan B, Shah SAA, Lim SM, Ramasamy K and Mani V (2018) Reverse pharmacophore mapping and molecular docking studies for discovery of GTPase HRas as promising drug target for bis-pyrimidine derivatives. *Chem Cent J* **12**(1): 106.
- Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT and Kliewer SA (1998) The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. *J Clin Invest* **102**(5): 1016-1023.

- Li L, Welch MA, Li Z, Mackowiak B, Heyward S, Swaan PW and Wang H (2019) Mechanistic Insights of Phenobarbital-Mediated Activation of Human but Not Mouse Pregnane X Receptor. *Mol Pharmacol* **96**(3): 345-354.
- Lin W and Chen T (2018) Using TR-FRET to Investigate Protein-Protein Interactions: A Case Study of PXR-Coregulator Interaction. *Adv Protein Chem Struct Biol* **110**: 31-63.
- Lin W, Goktug AN, Wu J, Currier DG and Chen T (2017a) High-Throughput Screening Identifies 1,4,5-Substituted 1,2,3-Triazole Analogs as Potent and Specific Antagonists of Pregnane X Receptor. *Assay Drug Dev Technol* **15**(8): 383-394.
- Lin W, Liu J, Jeffries C, Yang L, Lu Y, Lee RE and Chen T (2014) Development of BODIPY FL vindoline as a novel and high-affinity pregnane X receptor fluorescent probe. *Bioconjug Chem* 25(9): 1664-1677.
- Lin W, Wang YM, Chai SC, Lv L, Zheng J, Wu J, Zhang Q, Wang YD, Griffin PR and Chen T (2017b) SPA70 is a potent antagonist of human pregnane X receptor. *Nat Commun* **8**(1): 741.
- Lin W, Wu J, Dong H, Bouck D, Zeng FY and Chen T (2008) Cyclin-dependent kinase 2 negatively regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells. *J Biol Chem* **283**(45): 30650-30657.
- Maglich JM, Parks DJ, Moore LB, Collins JL, Goodwin B, Billin AN, Stoltz CA, Kliewer SA, Lambert MH, Willson TM and Moore JT (2003) Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. *J Biol Chem* 278(19): 17277-17283.
- Maglich JM, Stoltz CM, Goodwin B, Hawkins-Brown D, Moore JT and Kliewer SA (2002) Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. *Mol Pharmacol* **62**(3): 638-646.
- Mutoh S, Sobhany M, Moore R, Perera L, Pedersen L, Sueyoshi T and Negishi M (2013) Phenobarbital indirectly activates the constitutive active androstane receptor (CAR) by inhibition of epidermal growth factor receptor signaling. *Sci Signal* **6**(274): ra31.

- Nallani SC, Goodwin B, Maglich JM, Buckley DJ, Buckley AR and Desai PB (2003) Induction of cytochrome P450 3A by paclitaxel in mice: pivotal role of the nuclear xenobiotic receptor, pregnane X receptor. *Drug Metab Dispos* 31(5): 681-684.
- Oladimeji P, Cui H, Zhang C and Chen T (2016) Regulation of PXR and CAR by protein-protein interaction and signaling crosstalk. *Expert Opin Drug Metab Toxicol* **12**(9): 997-1010.
- Oladimeji PO and Chen T (2018) PXR: More Than Just a Master Xenobiotic Receptor. *Mol Pharmacol* **93**(2): 119-127.
- Roth A, Looser R, Kaufmann M, Blattler SM, Rencurel F, Huang W, Moore DD and Meyer UA (2008) Regulatory cross-talk between drug metabolism and lipid homeostasis: constitutive androstane receptor and pregnane X receptor increase Insig-1 expression. *Mol Pharmacol* **73**(4): 1282-1289.
- Sastry GM, Adzhigirey M, Day T, Annabhimoju R and Sherman W (2013) Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. *J Comput Aided Mol Des* **27**(3): 221-234.
- Schuetz EG, Schinkel AH, Relling MV and Schuetz JD (1996) P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. *Proc Natl Acad Sci* USA 93(9): 4001-4005.
- Tahlan S, Kumar S, Ramasamy K, Lim SM, Shah SAA, Mani V and Narasimhan B (2019) In-silico molecular design of heterocyclic benzimidazole scaffolds as prospective anticancer agents. *BMC Chem* 13(1): 90.
- Wang YM, Lin W, Chai SC, Wu J, Ong SS, Schuetz EG and Chen T (2013) Piperine activates human pregnane X receptor to induce the expression of cytochrome P450 3A4 and multidrug resistance protein 1. *Toxicol Appl Pharmacol* 272(1): 96-107.
- Wang YM, Ong SS, Chai SC and Chen T (2012) Role of CAR and PXR in xenobiotic sensing and metabolism. *Expert Opin Drug Metab Toxicol* **8**(7): 803-817.

- Xie W, Barwick JL, Simon CM, Pierce AM, Safe S, Blumberg B, Guzelian PS and Evans RM (2000) Reciprocal activation of xenobiotic response genes by nuclear receptors SXR/PXR and CAR. *Genes Dev* 14(23): 3014-3023.
- Xie Y, Xu M, Deng M, Li Z, Wang P, Ren S, Guo Y, Ma X, Fan J, Billiar TR and Xie W (2019)
 Activation of Pregnane X Receptor Sensitizes Mice to Hemorrhagic Shock-Induced Liver Injury.
 Hepatology 70(3): 995-1010.
- Yokobori K, Azuma I, Chiba K, Akita H, Furihata T and Kobayashi K (2019) Indirect activation of constitutive androstane receptor in three-dimensionally cultured HepG2 cells. *Biochem Pharmacol* **168**: 26-37.

118513

FOOTNOTES

This work was supported by ALSAC; St. Jude Children's Research Hospital; and the National Institutes of Health [grants R35GM118041 (to TC), P30-CA21765 (to the St. Jude Cancer Center)]. Primary human hepatocytes were obtained through the Liver Tissue and Cell Distribution System (Pittsburgh, PA), which was funded by NIH [Contract # HHSN276201200017C]. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

FIGURE LEGENDS

Fig. 1. CITCO binds directly to hPXR. Dose-response curves for T0901317, rifampicin (RIF), and CITCO in the hPXR TR-FRET binding assay are shown. Results are expressed as the mean ± SD of three independent experiments performed in quadruplicate. "%Inhibition" is determined as described in MATERIALS AND METHODS and represents the binding activity of the compound.

Fig. 2. CITCO activates hPXR in HepG2 cells stably expressing FLAG-hPXR-WT and CYP3A4-

luciferase. A. Dose-response curves for CITCO, rifampicin (RIF), and SPA70. B. Dose-response curves for CITCO in the presence of 0 nM, 100 nM, 500 nM, 1 μ M, 2 μ M, or 10 μ M SPA70. C. Dose-response curves for rifampicin (RIF) in the presence of 0 nM, 100 nM, 500 nM, 1 μ M, 2 μ M, or 10 μ M SPA70. D–F. Cytotoxicity assays corresponding to A–C, respectively. The activity of the hPXR-regulated *CYP3A4*-luciferase is used to measure the activation of hPXR and is expressed as "*CYP3A4* Promoter Activity," in relative luciferase unit (RLU) as described in MATERIALS AND METHODS. "%Relative Cytotoxicity" is calculated as described in MATERIALS AND METHODS. Results are expressed as the mean ± SD of three independent experiments performed in quadruplicate.

Fig. 3. CITCO activates hPXR-WT, but not hPXR-W299A or mPXR, in HEK293 cells. A. Doseresponse curves for rifampicin (RIF), CITCO, and PCN in HEK293 cells transiently transfected with FLAG-hPXR-WT, *CYP3A4*-luciferase, and pRL-TK (*Renilla* luciferase transfection control). B. Doseresponse curves for rifampicin (RIF), CITCO, and PCN in HEK293 cells transiently transfected with *CYP3A4*-luciferase and pRL-TK (without FLAG-hPXR-WT). C. Dose-response curves for rifampicin (RIF), CITCO, and PCN in HEK293 cells transiently transfected with CMV6-mPXR, *CYP3A4*-luciferase, and pRL-TK. D. Dose-response curves for rifampicin (RIF), CITCO, and PCN in HEK293 cells transiently transfected with FLAG-hPXR-W299A, *CYP3A4*-luciferase, and pRL-TK. E. Cytotoxicity of

rifampicin (RIF), CITCO, and PCN in HEK293 cells. Results are expressed as the mean ± SD of three independent experiments performed in quadruplicate.

Fig. 4. Computational docking analysis indicates that CITCO interacts with W299 of hPXR-WT through π - π interactions. CITCO (stick representation with carbon atoms in blue) residing in the ligand binding pocket of hPXR-WT (white) displaying π - π interactions with W299 (raspberry red). The ligand binding pocket of hPXR is partially displayed as white surface for clarity. The color scheme for the ligand represented as sticks: red, oxygen; yellow, sulfur; purple, nitrogen; green, chlorine.

Fig. 5. CITCO enhances the recruitment of coactivator SRC-1 to hPXR. A. Dose-response curves for T0901317, rifampicin (RIF), and CITCO in the hPXR TR-FRET coactivator recruitment assay. The TR-FRET signal (fold-to-DMSO), as described in MATERIALS AND METHODS, is used to represent hPXR–SRC-1 interaction. Results are expressed as the mean \pm SD of three independent experiments performed in quadruplicate. B. Mammalian two-hybrid assay in HepG2 cells. "Normalized luciferase (percentage of DMSO)" represents the interaction of hPXR with SRC-1 and is calculated by normalizing firefly luciferase activity to *Renilla* luciferase activity. Data are shown as the mean \pm SD (n = 3) (**p < 0.005; ***p < 0.001). The asterisks indicate significant difference between ligand treated (RIF and CITCO) compared to DMSO control samples (GAL4-SRC-1 + VP16-hPXR).

Fig. 6. CITCO induces CYP3A4 expression in HepaRG cells in an hPXR-dependent but hCAR-

independent manner. Differentiated parental (wild type, WT) and CAR KO HepaRG cells were treated with 5 μ M rifampicin (RIF); 10 μ M SPA70; 0.2, 1, or 10 μ M CITCO; or combinations as indicated for 24 or 72 h for mRNA and protein analysis, respectively. Cell homogenates from WT and CAR KO cells were analyzed for *CYP3A4* mRNA levels (A and C). The corresponding protein expression levels for WT

(B) and CAR KO (D) cells are shown. β -Actin was used as a protein loading control. For qRT-PCR analysis, data are shown as the mean \pm SD (n = 3) (*p < 0.05; ***p < 0.001).

Fig. 7. CITCO induces CYP3A4 expression in primary human hepatocytes (PHHs) in an hPXR-

dependent manner. PHHs (Donors #1–3) were treated with DMSO control; 1 μM rifampicin (RIF); 10 μM SPA70; 0.5, 1, 5 or 10 μM CITCO; or combinations as indicated for 72 h for mRNA (A) and protein (B) analysis. β-Actin was used as a protein loading control. For qRT-PCR analysis, data are shown as the mean \pm SD (n=3) (*p < 0.05; **p < 0.005; ***p < 0.001)

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5






Figure 6

С






В



HepaRG WT

D








Figure 7

